Curis, Inc. (NASDAQ:CRIS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.

According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “

A number of other research firms have also recently commented on CRIS. ValuEngine upgraded shares of Curis from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. BidaskClub cut shares of Curis from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $6.00.

Curis (CRIS) opened at 1.60 on Monday. The company’s market cap is $230.20 million. Curis has a 52 week low of $1.47 and a 52 week high of $3.72. The stock has a 50 day moving average of $1.77 and a 200 day moving average of $1.96.

Curis (NASDAQ:CRIS) last released its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). The company had revenue of $2.10 million during the quarter, compared to analyst estimates of $2.08 million. Curis had a negative return on equity of 236.43% and a negative net margin of 836.18%. The firm’s revenue for the quarter was up 23.5% on a year-over-year basis. During the same quarter last year, the business earned ($0.09) earnings per share. On average, analysts expect that Curis will post ($0.40) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Curis, Inc. (CRIS) Stock Rating Upgraded by Zacks Investment Research” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/curis-inc-cris-stock-rating-upgraded-by-zacks-investment-research/1637851.html.

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE raised its position in Curis by 58.7% during the 1st quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock worth $101,000 after buying an additional 13,448 shares during the last quarter. Prudential Financial Inc. purchased a new position in Curis during the 1st quarter worth approximately $105,000. Dynamic Technology Lab Private Ltd raised its position in Curis by 22.3% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 41,922 shares of the biotechnology company’s stock worth $117,000 after buying an additional 7,638 shares during the last quarter. OxFORD Asset Management LLP purchased a new position in Curis during the 2nd quarter worth approximately $115,000. Finally, Voya Investment Management LLC raised its position in Curis by 21.8% during the 2nd quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock worth $129,000 after buying an additional 12,207 shares during the last quarter. 44.72% of the stock is owned by institutional investors.

Curis Company Profile

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.